AARTI DRUGS LTD.
AARTIDRUGS · General/Diversified · NSE
₹375
Current Market Price
Fair Value (DCF)
₹356
Discount to FV
-5.2%
Updated just now
YieldIQ Score
51/100
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
42%
ROE
12.6%
Debt/Equity
0.37
WACC
11.1%
Market Cap
₹3,426 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
14.7%
Return on capital employed
EV / EBITDA
11.2×
Enterprise multiple
Debt / EBITDA
1.9×
Leverage vs earnings
Interest Coverage
6.9×
EBIT covers interest
Current Ratio
1.60×
Short-term liquidity
Asset Turnover
1.00×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-1.8%
3-year revenue growth
Revenue CAGR (5Y)
3.5%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹375.4
Bear case
Margin of Safety -519.1%
Implied upside -83.8%
Base case
Margin of Safety -5.8%
Implied upside -5.5%
Bull case
Margin of Safety +15.7%
Implied upside +18.6%
Ratio Trends
AARTIDRUGS · last 10 annual periods
ROE
12.6%
ROCE
14.7%
Operating Margin
—
Debt / Equity
0.37×
PE
15.0×
EV / EBITDA
11.2×
Historical Financials
AARTIDRUGS · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹2489 Cr | ₹2706 Cr | ₹2509 Cr | ₹2387 Cr | ₹2565 Cr | +0.8% |
| EBITDA | ₹341 Cr | ₹308 Cr | ₹320 Cr | ₹303 Cr | ₹312 Cr | -2.2% |
| EBIT | ₹291 Cr | ₹257 Cr | ₹269 Cr | — | — | -1.9% |
| PAT | ₹205 Cr | ₹166 Cr | ₹171 Cr | ₹168 Cr | ₹195 Cr | -1.3% |
| EPS (diluted) | ₹22.12 | ₹17.97 | ₹18.56 | — | — | -4.3% |
| CFO | ₹70.4 Cr | ₹133 Cr | ₹359 Cr | ₹245 Cr | ₹254 Cr | +37.8% |
| CapEx | ₹-152 Cr | ₹-165 Cr | ₹-226 Cr | ₹-177 Cr | ₹-173 Cr | — |
| FCF | ₹-81.6 Cr | ₹-31.5 Cr | ₹133 Cr | ₹67.4 Cr | ₹80.2 Cr | — |
| Total Assets | ₹2208 Cr | ₹2421 Cr | ₹2432 Cr | ₹2575 Cr | ₹2815 Cr | +6.3% |
| Total Debt | ₹543 Cr | ₹609 Cr | ₹564 Cr | ₹615 Cr | ₹577 Cr | +1.5% |
| Shareholders' Equity | ₹1036 Cr | ₹1192 Cr | ₹1282 Cr | ₹1369 Cr | ₹1549 Cr | +10.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
AARTIDRUGS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
NOVARTIND NOVARTIND | — | — | Pending | 11.4% | — |
 UNICHEMLAB UNICHEMLAB | — | — | Pending | 5.6% | — |
 RPGLIFE RPG LIFE SCIENCES LTD | -113.7%-53.2% upside | 40 | Above Fair Value | 20.3% | — |
 GUFICBIO GUFICBIO | — | — | Pending | 9.7% | 42.8× |
SOLARA SOLARA | — | — | Pending | 0.0% | — |
Click a ticker to view its fair-value analysis.
Dividend History
10 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹6.00/sh
Last payout
2026-02-09
₹2.00
Peak payout
₹2.50
Trailing yield
0.53%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. AARTI DRUGS LTD. (AARTIDRUGS.NS) trades at 375.40 vs a model fair value of 355.90, a gap of -5.2%. Piotroski F-score: 6/9. Moat label: Na...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of AARTIDRUGS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for AARTIDRUGS →
Compare
Head-to-head with peers
Compare AARTIDRUGS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse AARTIDRUGSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.